Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement Transl Res Clin Intervent. 2019;5:272–93.
Article
Google Scholar
Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis. 2018;64:S3–22.
Article
Google Scholar
Fargo KN, Carrillo MC, Weiner MW, Potter WZ, Khachaturian Z. The crisis in recruitment for clinical trials in Alzheimer’s and dementia: an action plan for solutions. Alzheimers Dement. 2016;12:1113–5.
Article
Google Scholar
Watson JL, Ryan L, Silverberg N, Cahan V, Bernard MA. Obstacles and opportunities in Alzheimer’s clinical trial recruitment. Health Aff. 2014;33:574–9.
Article
Google Scholar
Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer’s disease clinical trials. Alzheimers Res Ther. 2010;2:34.
Article
CAS
Google Scholar
Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, et al. Potential ethnic modifiers in the assessment and treatment of Alzheimer’s disease: challenges for the future. Int Psychogeriatr. 2007;19:539–58 Cambridge University Press.
Article
Google Scholar
2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020;16(3):391–460.
Riffin C, Van Ness PH, Wolff JL, Fried T. Family and other unpaid caregivers and older adults with and without dementia and disability. J Am Geriatr Soc. 2017;65:1821–8.
Article
Google Scholar
National Poll on Healthy Aging. Dementia Caregivers: Juggling, Delaying and Looking Forward. [Internet]. Available from: http://www.healthyagingpoll.org/sites/default/files/2017-10/NPHA_Caregivers-Report-PROOF_101817_v2.pdf.
Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013;80:282–8.
Article
Google Scholar
National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The prevention and treatment of missing data in clinical trials [Internet]. Washington (DC): National Academies Press (US); 2010. Available from: http://www.ncbi.nlm.nih.gov/books/NBK209904/.
Google Scholar
Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275–91.
Article
CAS
Google Scholar
Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS, et al. Randomized controlled trials in mild cognitive impairment: sources of variability. Neurology. 2017;88:1751–8.
Article
Google Scholar
Edland SD, Emond JA, Aisen PS, Petersen RC. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010;24:159–64.
Article
Google Scholar
Dording CM, Dalton ED, Pencina MJ, Fava M, Mischoulon D. Comparison of academic and nonacademic sites in multi-center clinical trials. J Clin Psychopharmacol. 2012;32:65–8.
Article
Google Scholar
Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen Y-F, et al. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials. Alzheimers Res Ther. 2015;7:39.
Article
Google Scholar
Cummings JL, Atri A, Ballard C, Boneva N, Frölich L, Molinuevo JL, et al. Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program. Alzheimers Res Ther. 2018;10:116.
Article
Google Scholar
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50 Massachusetts Medical Society.
Article
CAS
Google Scholar
Lilly Halts Development of Semagacestat for Alzheimer’s Disease Based on Preliminary Results of Phase III Clinical Trials [Internet]. Eli Lilly and Company. [cited 2020 May 4]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-halts-development-semagacestat-alzheimers-disease-based.
Henley DB, Dowsett SA, Chen Y-F, Liu-Seifert H, Grill JD, Doody RS, et al. Alzheimer’s disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther. 2015;7:43.
Article
Google Scholar
Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat. 2008;2:841–60.
Article
Google Scholar
Ishwaran H, Kogalur UB. randomForestSRC: fast unified random forests for survival, regression, and classification (RF-SRC) [Internet]. 2020. Available from: https://CRAN.R-project.org/package=randomForestSRC.
Google Scholar
Ishwaran H, Kogalur U. Random survival forests for R. R News. 2007;7:25–31.
Google Scholar
R Core Team. R: a language and environment for statistical computing [Internet]. Vienna: R Foundation for Statistical Computing; 2019. Available from: https://www.R-project.org/.
Google Scholar
Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer’s disease studies: what can we learn? Alzheimers Dement J Alzheimers Assoc. 2015;11:24–31.
Article
Google Scholar
Shin J, Doraiswamy PM. Underrepresentation of African-Americans in Alzheimer’s trials: a call for affirmative action. Front Aging Neurosci. 2016;8:123.
Article
Google Scholar
Nuño MM, Gillen DL, Dosanjh KK, Brook J, Elashoff D, Ringman JM, et al. Attitudes toward clinical trials across the Alzheimer’s disease spectrum. Alz Res Ther. 2017;9:81.
Article
Google Scholar
Koss E, Peterson B, Fillenbaum GG. Determinants of attrition in a natural history study of Alzheimer disease. Alzheimer Dis Assoc Disord. 1999;13:209–15.
Article
CAS
Google Scholar
Coley N, Gardette V, Toulza O, Gillette-Guyonnet S, Cantet C, Nourhashemi F, et al. Predictive factors of attrition in a cohort of Alzheimer disease patients. The REAL.FR study. Neuroepidemiology. 2008;31:69–79.
Article
Google Scholar
Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012;69:901–5.
Article
Google Scholar
Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015;84:1121–7.
Article
Google Scholar
Bernard MA, Clayton JA, Lauer MS. Inclusion across the lifespan: NIH policy for clinical research. JAMA. 2018;320:1535–6.
Article
Google Scholar
Largent EA, Fernandez LH. Making the case for completion bonuses in clinical trials. Clin Trials. 2019;16:176–82.
Article
Google Scholar
Largent EA, Karlawish J, Grill JD. Study partners: essential collaborators in discovering treatments for Alzheimer’s disease. Alzheimers Res Ther. 2018;10:101.
Article
Google Scholar
Brewster P, Barnes L, Haan M, Johnson JK, Manly JJ, Nápoles AM, et al. Progress and future challenges in aging and diversity research in the United States. Alzheimers Dement. 2019;15:995–1003.
Article
Google Scholar
Robinson KA, Dinglas VD, Sukrithan V, Yalamanchilli R, Mendez-Tellez PA, Dennison-Himmelfarb C, et al. Updated systematic review identifies substantial number of retention strategies: using more strategies retains more study participants. J Clin Epidemiol. 2015;68:1481–7.
Article
Google Scholar
Vernon EK, Cooley B, Rozum W, Rattinger GB, Behrens S, Matyi J, et al. Caregiver-care recipient relationship closeness is associated with neuropsychiatric symptoms in dementia. The American Journal of Geriatric Psychiatry. Elsevier. 2019;27:349–59.
Google Scholar
Rattinger GB, Fauth EB, Behrens S, Sanders C, Schwartz S, Norton MC, et al. Closer caregiver and care-recipient relationships predict lower informal costs of dementia care: the Cache County Dementia Progression Study. Alzheimers Dement. 2016;12:917–24.
Article
Google Scholar
Fauth E, Hess K, Piercy K, Norton M, Corcoran C, Rabins P, et al. Caregivers’ relationship closeness with the person with dementia predicts both positive and negative outcomes for caregivers’ physical health and psychological well-being. Aging Ment Health. 2012;16:699–711.
Article
Google Scholar
Norton MC, Piercy KW, Rabins PV, Green RC, Breitner JCS, Ostbye T, et al. Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci. 2009;64:560–8.
Article
Google Scholar